PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION
Market segmentation by application
Comparison by application
Autoimmune disorders - Market size and forecast 2018-2023
Oncology - Market size and forecast 2018-2023
Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges

PART 11: MARKET TRENDS
Increasing research grants
Special drug designations
Rising number of strategic alliances

PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario

PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Astellas Pharma Inc.
Eli Lilly and Co.
Incyte Corp.
Novartis AG
Pfizer Inc.

PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Autoimmune disorders - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Pipeline of JAK inhibitors for autoimmune disorders
Exhibit 22: Autoimmune disorders - Year-over-year growth 2019-2023 (%)
Exhibit 23: Oncology - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Pipeline of JAK inhibitors for oncology
Exhibit 25: Oncology - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Astellas Pharma Inc. - Vendor overview
Exhibit 51: Astellas Pharma Inc. - Business segments
Exhibit 52: Astellas Pharma Inc. - Organizational developments
Exhibit 53: Astellas Pharma Inc. - Geographic focus
Exhibit 54: Astellas Pharma Inc. - Key offerings
Exhibit 55: Astellas Pharma Inc. - Key customers
Exhibit 56: Eli Lilly and Co. - Vendor overview
Exhibit 57: Eli Lilly and Co. - Business segments
Exhibit 58: Eli Lilly and Co. - Organizational developments
Exhibit 59: Eli Lilly and Co. - Geographic focus
Exhibit 60: Eli Lilly and Co. - Segment focus
Exhibit 61: Eli Lilly and Co. - Key offerings
Exhibit 62: Eli Lilly and Co. - Key customers
Exhibit 63: Incyte Corp. - Vendor overview
Exhibit 64: Incyte Corp. - Business segments
Exhibit 65: Incyte Corp. - Organizational developments
Exhibit 66: Incyte Corp. - Geographic focus
Exhibit 67: Incyte Corp. - Key offerings
Exhibit 68: Incyte Corp. - Key customers
Exhibit 69: Novartis AG - Vendor overview
Exhibit 70: Novartis AG - Business segments
Exhibit 71: Novartis AG - Organizational developments
Exhibit 72: Novartis AG - Geographic focus
Exhibit 73: Novartis AG - Segment focus
Exhibit 74: Novartis AG - Key offerings
Exhibit 75: Novartis AG - Key customers
Exhibit 76: Pfizer Inc. - Vendor overview
Exhibit 77: Pfizer Inc. - Business segments
Exhibit 78: Pfizer Inc. - Organizational developments
Exhibit 79: Pfizer Inc. - Geographic focus
Exhibit 80: Pfizer Inc. - Segment focus
Exhibit 81: Pfizer Inc. - Key offerings
Exhibit 82: Pfizer Inc. - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors

Companies Mentioned
• Astellas Pharma Inc.
• Eli Lilly and Co.
• Incyte Corp.
• Novartis AG
• Pfizer Inc.